CIRAX | RAPAX | CIRAX / RAPAX | |
Total Expense Ratio | 0.62 | 1.16 | 53% |
Annual Report Gross Expense Ratio | 0.62 | 1.28 | 48% |
Fund Existence | 24 years | 14 years | - |
Gain YTD | 15.337 | 11.252 | 136% |
Front Load | 4% | 5% | 78% |
Min. Initial Investment | 250 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 118B | 1.3B | 9,077% |
Annual Yield % from dividends | 2.90 | 2.12 | 137% |
Returns for 1 year | 11.89 | 9.06 | 131% |
Returns for 3 years | 40.44 | 17.79 | 227% |
Returns for 5 years | 55.33 | 52.50 | 105% |
Returns for 10 years | 94.63 | 72.26 | 131% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
GNOM | 37.99 | 0.91 | +2.44% |
Global X Genomics & Biotechnology ETF | |||
MQY | 11.19 | 0.15 | +1.36% |
Blackrock Muni Yield Quality Fund | |||
AVSD | 70.10 | 0.41 | +0.59% |
Avantis Responsible International Eq ETF | |||
VYM | 139.55 | 0.26 | +0.19% |
Vanguard High Dividend Yield ETF | |||
LGCF | 33.00 | N/A | N/A |
Themes US Cash Flow Champions ETF |